NCT07729787 Autogenic Drainage Versus Mechanical Percussion in Children With Cystic Fibrosis
| NCT ID | NCT07729787 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Riphah International University |
| Condition | Cystic Fibrosis (CF) |
| Study Type | INTERVENTIONAL |
| Enrollment | 32 participants |
| Start Date | 2026-06-14 |
| Primary Completion | 2026-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 32 participants in total. It began in 2026-06-14 with a primary completion date of 2026-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to compare the effects of autogenic drainage and mechanical percussion on lung function, dyspnea, and quality of life in children with cystic fibrosis. The main questions it aims to answer are: * Does autogenic drainage improve lung function more effectively than mechanical percussion in children with cystic fibrosis? * Does autogenic drainage reduce dyspnea (breathlessness) more effectively than mechanical percussion? * Does autogenic drainage improve health-related quality of life more effectively than mechanical percussion? Researchers will compare autogenic drainage with mechanical percussion to determine which airway clearance technique provides greater benefits for children with cystic fibrosis. Participants will: * Be randomly assigned to receive either autogenic drainage or mechanical percussion therapy. * Participate in supervised treatment sessions five times per week for six weeks. * Undergo assessments of lung function using spirometry (FEV₁ and FVC), dyspnea using the Modified Borg Dyspnea Scale, and quality of life using the Cystic Fibrosis Questionnaire-Revised (CFQ-R) before and after the intervention period. The findings of this study may help identify the most effective airway clearance technique for improving respiratory health and quality of life in children with cystic fibrosis.
Eligibility Criteria
Inclusion Criteria: * Confirmed diagnosis of cystic fibrosis (CF) through a sweat test or genetic testing. * Age between 6 and 12 years. * Clinically stable condition (no acute pulmonary exacerbation within the last 4 weeks). Exclusion Criteria: * History of thoracic surgery. * Active hemoptysis. * Severe physical or cognitive disabilities limiting participation in the intervention or assessments.
Contact & Investigator
Humera Ayub, MS-CPPT
PRINCIPAL INVESTIGATOR
Riphah International University
Frequently Asked Questions
Who can join the NCT07729787 clinical trial?
This trial is open to participants of all sexes, aged 6 Years or older, up to 12 Years, studying Cystic Fibrosis (CF). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07729787 currently recruiting?
Yes, NCT07729787 is actively recruiting participants. Contact the research team at imran.amjad@riphah.edu.pk for enrollment information.
Where is the NCT07729787 trial being conducted?
This trial is being conducted at Multan Khurd, Pakistan.
Who is sponsoring the NCT07729787 clinical trial?
NCT07729787 is sponsored by Riphah International University. The principal investigator is Humera Ayub, MS-CPPT at Riphah International University. The trial plans to enroll 32 participants.